English
简体中文
Total: £ 56.28
Published Date: 2024-10-17 | Pages: 126 | Tables: 239 | Pharma & Healthcare
Epidemic Japanese encephalitis (hereinafter referred to as "JE") is an acute infectious disease of the central nervous system caused by the Japanese encephalitis virus, with inflammation of the brain parenchyma as the main lesion.
The global market for Live Attenuated Japanese Encephalitis Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Live Attenuated Japanese Encephalitis Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Live Attenuated Japanese Encephalitis Vaccine by region & country, by Type, and by Application.
The Live Attenuated Japanese Encephalitis Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Japanese Encephalitis Vaccine.
Market Segmentation
By Company
Novartis
Sanofi
Chengdu Institute of Biological Products
Wuhan Institute of Biological Products
Lanzhou Institute of Biological Products
Beijing Temple of Heaven Biological Products
Valneva
Bharat Biotech
Cheng Da Biology
Biocelect Pty Ltd
Glovax Co., Ltd.
Segment by Type:
0.5ml
1ml
2.5ml
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Live Attenuated Japanese Encephalitis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Live Attenuated Japanese Encephalitis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Live Attenuated Japanese Encephalitis Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Live Attenuated Japanese Encephalitis Vaccine Product Introduction
1.2 Global Live Attenuated Japanese Encephalitis Vaccine Market Size Forecast
1.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value (2019-2030)
1.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume (2019-2030)
1.2.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Price (2019-2030)
1.3 Live Attenuated Japanese Encephalitis Vaccine Market Trends & Drivers
1.3.1 Live Attenuated Japanese Encephalitis Vaccine Industry Trends
1.3.2 Live Attenuated Japanese Encephalitis Vaccine Market Drivers & Opportunity
1.3.3 Live Attenuated Japanese Encephalitis Vaccine Market Challenges
1.3.4 Live Attenuated Japanese Encephalitis Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Live Attenuated Japanese Encephalitis Vaccine Players Revenue Ranking (2023)
2.2 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Company (2019-2024)
2.3 Global Live Attenuated Japanese Encephalitis Vaccine Players Sales Volume Ranking (2023)
2.4 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers Live Attenuated Japanese Encephalitis Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Live Attenuated Japanese Encephalitis Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Live Attenuated Japanese Encephalitis Vaccine
2.9 Live Attenuated Japanese Encephalitis Vaccine Market Competitive Analysis
2.9.1 Live Attenuated Japanese Encephalitis Vaccine Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Live Attenuated Japanese Encephalitis Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Japanese Encephalitis Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 0.5ml
3.1.2 1ml
3.1.3 2.5ml
3.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type
3.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type
3.3.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application
4.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application
4.3.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region
5.1.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Region
5.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
5.4.2 North America Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
5.5.2 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
5.7.2 South America Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Value
6.2.1 Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
6.3.2 United States Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
6.4.2 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
6.5.2 China Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
6.6.2 Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
6.7.2 South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019-2030
6.9.2 India Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Company Information
7.1.2 Novartis Introduction and Business Overview
7.1.3 Novartis Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Novartis Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.1.5 Novartis Recent Development
7.2 Sanofi
7.2.1 Sanofi Company Information
7.2.2 Sanofi Introduction and Business Overview
7.2.3 Sanofi Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Sanofi Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.2.5 Sanofi Recent Development
7.3 Chengdu Institute of Biological Products
7.3.1 Chengdu Institute of Biological Products Company Information
7.3.2 Chengdu Institute of Biological Products Introduction and Business Overview
7.3.3 Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.3.5 Chengdu Institute of Biological Products Recent Development
7.4 Wuhan Institute of Biological Products
7.4.1 Wuhan Institute of Biological Products Company Information
7.4.2 Wuhan Institute of Biological Products Introduction and Business Overview
7.4.3 Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.4.5 Wuhan Institute of Biological Products Recent Development
7.5 Lanzhou Institute of Biological Products
7.5.1 Lanzhou Institute of Biological Products Company Information
7.5.2 Lanzhou Institute of Biological Products Introduction and Business Overview
7.5.3 Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.5.5 Lanzhou Institute of Biological Products Recent Development
7.6 Beijing Temple of Heaven Biological Products
7.6.1 Beijing Temple of Heaven Biological Products Company Information
7.6.2 Beijing Temple of Heaven Biological Products Introduction and Business Overview
7.6.3 Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.6.5 Beijing Temple of Heaven Biological Products Recent Development
7.7 Valneva
7.7.1 Valneva Company Information
7.7.2 Valneva Introduction and Business Overview
7.7.3 Valneva Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Valneva Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.7.5 Valneva Recent Development
7.8 Bharat Biotech
7.8.1 Bharat Biotech Company Information
7.8.2 Bharat Biotech Introduction and Business Overview
7.8.3 Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.8.5 Bharat Biotech Recent Development
7.9 Cheng Da Biology
7.9.1 Cheng Da Biology Company Information
7.9.2 Cheng Da Biology Introduction and Business Overview
7.9.3 Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.9.5 Cheng Da Biology Recent Development
7.10 Biocelect Pty Ltd
7.10.1 Biocelect Pty Ltd Company Information
7.10.2 Biocelect Pty Ltd Introduction and Business Overview
7.10.3 Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.10.5 Biocelect Pty Ltd Recent Development
7.11 Glovax Co., Ltd.
7.11.1 Glovax Co., Ltd. Company Information
7.11.2 Glovax Co., Ltd. Introduction and Business Overview
7.11.3 Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Product Offerings
7.11.5 Glovax Co., Ltd. Recent Development
8 Industry Chain Analysis
8.1 Live Attenuated Japanese Encephalitis Vaccine Industrial Chain
8.2 Live Attenuated Japanese Encephalitis Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Live Attenuated Japanese Encephalitis Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Live Attenuated Japanese Encephalitis Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Live Attenuated Japanese Encephalitis Vaccine Market Trends
Table 2. Live Attenuated Japanese Encephalitis Vaccine Market Drivers & Opportunity
Table 3. Live Attenuated Japanese Encephalitis Vaccine Market Challenges
Table 4. Live Attenuated Japanese Encephalitis Vaccine Market Restraints
Table 5. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Company (2019-2024)
Table 7. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Live Attenuated Japanese Encephalitis Vaccine Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Live Attenuated Japanese Encephalitis Vaccine Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Live Attenuated Japanese Encephalitis Vaccine Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Live Attenuated Japanese Encephalitis Vaccine
Table 13. Global Live Attenuated Japanese Encephalitis Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Japanese Encephalitis Vaccine as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Live Attenuated Japanese Encephalitis Vaccine Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Live Attenuated Japanese Encephalitis Vaccine Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Live Attenuated Japanese Encephalitis Vaccine Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Live Attenuated Japanese Encephalitis Vaccine Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (2019-2024) & (%)
Table 44. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (2025-2030) & (%)
Table 45. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Region (2019-2024) & (%)
Table 49. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Region (2025-2030) & (%)
Table 50. Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Volume, (2025-2030) & (K Units)
Table 57. Novartis Company Information
Table 58. Novartis Introduction and Business Overview
Table 59. Novartis Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Novartis Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 61. Novartis Recent Development
Table 62. Sanofi Company Information
Table 63. Sanofi Introduction and Business Overview
Table 64. Sanofi Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Sanofi Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 66. Sanofi Recent Development
Table 67. Chengdu Institute of Biological Products Company Information
Table 68. Chengdu Institute of Biological Products Introduction and Business Overview
Table 69. Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 71. Chengdu Institute of Biological Products Recent Development
Table 72. Wuhan Institute of Biological Products Company Information
Table 73. Wuhan Institute of Biological Products Introduction and Business Overview
Table 74. Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 76. Wuhan Institute of Biological Products Recent Development
Table 77. Lanzhou Institute of Biological Products Company Information
Table 78. Lanzhou Institute of Biological Products Introduction and Business Overview
Table 79. Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 81. Lanzhou Institute of Biological Products Recent Development
Table 82. Beijing Temple of Heaven Biological Products Company Information
Table 83. Beijing Temple of Heaven Biological Products Introduction and Business Overview
Table 84. Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 86. Beijing Temple of Heaven Biological Products Recent Development
Table 87. Valneva Company Information
Table 88. Valneva Introduction and Business Overview
Table 89. Valneva Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Valneva Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 91. Valneva Recent Development
Table 92. Bharat Biotech Company Information
Table 93. Bharat Biotech Introduction and Business Overview
Table 94. Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 96. Bharat Biotech Recent Development
Table 97. Cheng Da Biology Company Information
Table 98. Cheng Da Biology Introduction and Business Overview
Table 99. Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 101. Cheng Da Biology Recent Development
Table 102. Biocelect Pty Ltd Company Information
Table 103. Biocelect Pty Ltd Introduction and Business Overview
Table 104. Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 106. Biocelect Pty Ltd Recent Development
Table 107. Glovax Co., Ltd. Company Information
Table 108. Glovax Co., Ltd. Introduction and Business Overview
Table 109. Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Product Offerings
Table 111. Glovax Co., Ltd. Recent Development
Table 112. Key Raw Materials Lists
Table 113. Raw Materials Key Suppliers Lists
Table 114. Live Attenuated Japanese Encephalitis Vaccine Downstream Customers
Table 115. Live Attenuated Japanese Encephalitis Vaccine Distributors List
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Live Attenuated Japanese Encephalitis Vaccine Product Picture
Figure 2. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume (2019-2030) & (K Units)
Figure 5. Global Live Attenuated Japanese Encephalitis Vaccine Sales Price (2019-2030) & (US$/Unit)
Figure 6. Live Attenuated Japanese Encephalitis Vaccine Report Years Considered
Figure 7. Global Live Attenuated Japanese Encephalitis Vaccine Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Live Attenuated Japanese Encephalitis Vaccine Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Live Attenuated Japanese Encephalitis Vaccine Revenue in 2023
Figure 10. Live Attenuated Japanese Encephalitis Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. 0.5ml Picture
Figure 12. 1ml Picture
Figure 13. 2.5ml Picture
Figure 14. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 17. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Live Attenuated Japanese Encephalitis Vaccine Price by Type (2019-2030) & (US$/Unit)
Figure 19. Product Picture of Hospital
Figure 20. Product Picture of Clinic
Figure 21. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Market Share by Application, 2023 & 2030
Figure 23. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Market Share by Application, 2023 & 2030
Figure 25. Global Live Attenuated Japanese Encephalitis Vaccine Price by Application (2019-2030) & (US$/Unit)
Figure 26. North America Live Attenuated Japanese Encephalitis Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 27. North America Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 28. Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 30. Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 32. South America Live Attenuated Japanese Encephalitis Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 33. South America Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 36. Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Value (%), (2019-2030)
Figure 37. Key Countries/Regions Live Attenuated Japanese Encephalitis Vaccine Sales Volume (%), (2019-2030)
Figure 38. United States Live Attenuated Japanese Encephalitis Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 39. United States Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 40. United States Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 41. Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 42. Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 43. Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 44. China Live Attenuated Japanese Encephalitis Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 45. China Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 46. China Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 47. Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 48. Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 49. Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 50. South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 51. South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 52. South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 53. Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 54. Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 55. Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 56. India Live Attenuated Japanese Encephalitis Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 57. India Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 58. India Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 59. Live Attenuated Japanese Encephalitis Vaccine Industrial Chain
Figure 60. Live Attenuated Japanese Encephalitis Vaccine Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
